The ROCA Test is a blood test that determines the risk of a woman having ovarian cancer. The test is intended for women over 35 with a mutation in the BRCA1 or BRCA2 gene that confers a high risk of developing ovarian cancer.
Women with a BRCA1 or BRCA2 gene mutation are generally recommended to consider preventative surgery (removal of both ovaries and fallopian tubes). However, this results in early menopause and affects fertility. For women who choose to delay this procedure, the ROCA Test may be a helpful option.
The ROCA Test is not yet available the NHS but can be obtained via privately through one of our expert clinicians offering ROCA Care. Current clinics are located in Cardiff and London.
The ROCA Test is intended for women who are over 35 years old, have tested positive for BRCA1 or BRCA2 gene mutation and wish to delay risk reducing surgery.
Any woman interested in having survellance using the ROCA Test must have a consultation with a clinician, so that she can understand the latest clinical evidence, and gain an informed view on the benefits and risks of using the ROCA Test. During the consultation, the clinician will assess your risk of ovarian cancer and your suitability for the test. Anyone interested should please get in touch with us at contact us and we can find a clinician near you.
University College London Hospitals NHS Foundation Trust (UCLH), in collaboration with the NHS North Central London Cancer Alliance (NCLCA) and GENinCode Plc, becomes the first hospital trust in the country to provide a new ovarian cancer (OC) surveillance testing service as part of its Familial Cancer Clinic. The service, in line with new NICE (National Institute for Health and Care Excellence) guidance1, is for women who have a high risk of ovarian cancer due to inherited BRCA1 or BRCA2 gene alterations, who wish to defer preventative surgery.
Read moreUniversity College London Hospitals NHS Foundation Trust (UCLH), in collaboration with the NHS North Central London Cancer Alliance (NCLCA) and GENinCode Plc, becomes the first hospital trust in the country to provide a new ovarian cancer (OC) surveillance testing service as part of its Familial Cancer Clinic. The service, in line with new NICE (National Institute for Health and Care Excellence) guidance1, is for women who have a high risk of ovarian cancer due to inherited BRCA1 or BRCA2 gene alterations, who wish to defer preventative surgery.
Read more
